Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma

Nature Genetics

Volumn 43, Issue 11, 2011, Pages 1119-1126

  Prickett, Todd D ^a   Wei, Xiaomu ^a   Cardenas Navia, Isabel ^a   Teer, Jamie K ^a   Lin, Jimmy C ^b   Walia, Vijay ^a   Gartner, Jared ^a   Jiang, Jiji ^a   Cherukuri, Praveen F ^a   Molinolo, Alfredo ^c   Davies, Michael A ^d   Gershenwald, Jeffrey E ^d   Stemke Hale, Katherine ^d   Rosenberg, Steven A ^e   Margulies, Elliott H ^a   Samuels, Yardena ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SELUMETINIB; SHORT HAIRPIN RNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXON; GENE MUTATION; MELANOMA; MELANOMA CELL; MOUSE; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOMATIC MUTATION;

EXONS; HUMANS; MELANOMA; MUTATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 80054997116     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.950     Document Type: Article

References (22)

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
3. Dorsam, R.T. & Gutkind, J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79-94 (2007). (Pubitemid 46164746)
4. Lee, H.J., Wall, B. & Chen, S. G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res 21, 415-428 (2008). (Pubitemid 351990969)
5. Flower, D.R. Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. Acta 1422, 207-234 (1999). (Pubitemid 29512378)
6. Porreca, G.J. et al. Multiplex amplification of large sets of human exons. Nat. Methods 4, 931-936 (2007). (Pubitemid 350042382)
7. Prickett, T.D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132 (2009).
8. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007). (Pubitemid 46398669)
9. Ng, P.C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003). (Pubitemid 37442253)
10. Pollock, P.M. et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108-112 (2003). (Pubitemid 36548800)
11. Davies, M.A. et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538-7546 (2009).
12. Aronica, E. et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur. J. Neurosci. 17, 2106-2118 (2003). (Pubitemid 36713971)
13. Brabet, I. et al. Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-l-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37, 1043-1051 (1998). (Pubitemid 28401493)
14. Nishi, N., Odagaki, Y. & Koyama, T. Pharmacological characterization of metabotropic glutamate receptor-mediated high-affinity GTPase activity in rat cerebral cortical membranes. Br. J. Pharmacol. 130, 1664-1670 (2000). (Pubitemid 30611946)
15. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006). (Pubitemid 43128863)
16. Bian, D. et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 64, 4209-4217 (2004). (Pubitemid 38802425)
17. Yu, J.J. et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc. Natl. Acad. Sci. USA 106, 2635-2640 (2009).
18. McDermott, D.F. et al. Double-blind randomized phase 2 study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26, 2178-2185 (2008).
19. Rinehart, J. et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462 (2004). (Pubitemid 41185111)
20. Palavalli, L.H. et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet. 41, 518-520 (2009).
21. Viloria, C.G. et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 69, 4926-4934 (2009).
22. Wei, X. et al. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol. Cancer Res. 8, 1513-1525 (2010).